FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...

Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

GSK will acquire a Chimagen trispecific T cell engager for multiple myeloma in a deal worth up to $750M. Here's what it means ...

GSK to acquire potential best-in-class T cell-engager for multiple myeloma from Chimagen Biosciences: London, UK Wednesday, September 16, 2026, 09:00 Hrs [IST] GSK plc announced i ...

GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical ...

GSK has agreed to pay up to $750 million for global rights to a trispecific T-cell engager from Chinese biotech Chimagen Biosciences, ...

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences. Trispecific TCE targeting T cells ...

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $750 million for an experimental cancer therapy from the privately owned Chinese biotech Chimagen Biosciences. The pharmaceuticals group will hand ...

GSK has agreed to pay up to $750 million for an experimental cancer therapy from the privately owned Chinese biotech Chimagen Biosciences. The pharmaceuticals group will hand over an undisclosed ...

British pharmaceutical giant GSK announced a deal worth up to $750 million to acquire global rights to a trispecific T cell engager from ...

Pharmaceutical major GSK plans to shut its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting around 641 jobs at risk and triggering opposition from the plant’s works council ...

As one notable company exits the field, growing CDMOs open facilities and secure major contracts ...